Delivery from the reservoir patch was not as effective as the matrix. Due to the evident superiority of the matrix patch over the reservoir system, as well as its greater potential to reduce drug abuse, Phosphagenics will continue its development program with the matrix patch.

The oxycodone Phase 1b trial was a very critical study and a milestone for Phosphagenics, going beyond a proof of concept and demonstrating that our patch system can reproducibly deliver therapeutic amounts of oxycodone into the blood stream. The therapeutic blood levels, the rapid elimination and the lack of irritation observed during the study, together with the likelihood that the patch will reduce drug abuse, makes it extremely attractive commercially, said Dr Esra Ogru, Phosphagenics ™ Chief Operating Officer. The continued increase in oxycodone concentrations over the duration of the experiment surpassed even our own expectations, and further validates the power of TPM?„? for transdermal delivery. We believe that this product will be ideal for management of chronic pain.

As a consequence of this breakthrough clinical trial, Phosphagenics is planning the next stage of its oxycodone development. Under the guidance of Professor Guy Ludbrook, Phosphagenics has assembled an advisory panel of international pain experts to plan the path forward into phase 2/3 trials and beyond. It expects to commence its next clinical study in the second half of this year.